|1.||Zhang, Chang-Le: 2 articles (08/2014 - 01/2011)|
|2.||Meng, Xiang-Ling: 2 articles (08/2014 - 01/2011)|
|3.||Wu, Wen-Yong: 2 articles (08/2014 - 01/2011)|
|4.||Wu, Zheng-Sheng: 2 articles (08/2014 - 01/2011)|
|5.||Ma, Tao: 2 articles (12/2012 - 01/2012)|
|6.||Chen, Wei: 2 articles (12/2012 - 01/2012)|
|7.||Willingham, Mark C: 1 article (01/2016)|
|8.||Park, Jeong Won: 1 article (01/2016)|
|9.||Cheng, Sheue-Yann: 1 article (01/2016)|
|10.||Zhao, Li: 1 article (01/2016)|
|1.||Hepatocellular Carcinoma (Hepatoma)
02/19/2009 - "The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling."
01/01/2012 - "To evaluate the efficacy of combination therapy using cetuximab and NSC 74859 (a novel STAT3 inhibitor) in EGFR and STAT3 overexpressing hepatoma cells. "
12/28/2012 - "NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells."
01/01/2012 - "Enhanced growth inhibition in hepatoma cells treated with both NSC 74859 and cetuximab suggests that cetuximab resistance is probably mediated via STAT3. "
01/01/2012 - "Hepatoma cell lines were treated with cetuximab, NSC 74859 or a combination of both drugs. "
01/01/2016 - "S3I-201 effectively inhibited HFD-induced aberrant activation of STAT3 and its downstream targets to markedly inhibit thyroid tumor growth and to prolong survival. "
08/01/2014 - "HCC tumors developed in mice by DEN-induction with administration of NSC 74859 resulted in decreased expression of c-myc, MMP-2, and MMP-9, but not SOCS3. "
01/01/2011 - "In this animal model, blockade of STAT3 with NSC 74859 induced tumor cell apoptosis, while inhibiting both tumor cells and monocytes proliferation. "
01/01/2011 - "The STAT3 inhibitor, NSC 74859, significantly suppressed tumor growth in vivo in mice with diethylinitrosamine (DEN)-induced HCC. "
05/01/2007 - "These findings strongly suggest that the antitumor activity of S3I-201 is mediated in part through inhibition of aberrant Stat3 activation and provide the proof-of-concept for the potential clinical use of Stat3 inhibitors such as S3I-201 in tumors harboring aberrant Stat3."
11/01/2013 - "Our studies suggest that treating infection with both S3i-201 and MBV is a novel approach to inhibit hCMV replication. "
11/01/2013 - "Upon combining S3i-201 with MBV, our data suggest that STAT3 inhibition is acting synergistically with MBV to inhibit infection in vitro. "
11/01/2013 - "The addition of the STAT3 inhibitor, S3i-201, during infection altered hCMV-mediated changes in cell cycle protein expression. "
01/10/2012 - "Small-molecule inhibitors of STAT3 phosphorylation and survivin restrict VZV replication in vitro, and VZV infection of skin xenografts in vivo is markedly impaired by the administration of the phospho-STAT3 inhibitor S3I-201. "
|5.||Thyroid Neoplasms (Thyroid Cancer)
01/01/2016 - "We assessed the effects of S3I-201 on HFD-induced thyroid cancer progression, the leptin-JAK2-STAT3 signaling pathway, and key regulators of epithelial-mesenchymal transition (EMT). "
01/01/2016 - "The aim of the present study was to evaluate the effect of S3I-201, a specific inhibitor of STAT3 activity, on HFD-induced aggressive cancer progression in the mouse model of thyroid cancer. "
|1.||Transforming Growth Factor beta (TGF-beta)
|3.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
|4.||Interleukin-6 (Interleukin 6)
|5.||Cytokine Receptor gp130
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|10.||Immunoglobulin Fc Fragments
|2.||Heterologous Transplantation (Xenotransplantation)